Abstract

Basic scientists and clinicians will collaborate to study the biology of human lymphoma cells, improve the cure rate while decreasing the toxidity of current therapy for lymphoma, and develop new modalities of treatment. Human lymphoma cells will be phenotyped with monoclonal antibodies, and nucleic acid probes. They will be established as cell lines in tissue culture. Their tissue homing properties will be examined. A series of controlled clinical trials will be performed for adults and children with all stages of Hodgkin's disease. The results of our ongoing clinical trials will be used to design new protocols of radiotherapy and chemotherapy. Outcome data will be accumulated and anlyzed in terms of response rate and cure with special attention to the long-term morbidity of treatment. New approaches to statistical methods will be studied. Patients with non-Hodgkin's lymphomas will be studied with sensitive genetic probes and monoclonal antibodies to determine their disease stage, treatment response, recurrence, clonality and their candidacy for novel therapies with monoclonal antibodies, lymphokines and interferon.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA034233-04
Application #
3093545
Study Section
Clinical Cancer Program Project Review Committee (CCP)
Project Start
1986-04-01
Project End
1991-03-31
Budget Start
1986-04-01
Budget End
1987-03-31
Support Year
4
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
Stanford University
Department
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305

  Publications

Myklebust, June H; Brody, Joshua; Kohrt, Holbrook E et al. (2017) Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood 129:759-770
Anchang, Benedict; Hart, Tom D P; Bendall, Sean C et al. (2016) Visualization and cellular hierarchy inference of single-cell data using SPADE. Nat Protoc 11:1264-79
Sagiv-Barfi, Idit; Kohrt, Holbrook E; Burckhardt, Laura et al. (2015) Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. Blood 125:2079-86
Behbehani, Gregory K; Samusik, Nikolay; Bjornson, Zach B et al. (2015) Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. Cancer Discov 5:988-1003
Levine, Jacob H; Simonds, Erin F; Bendall, Sean C et al. (2015) Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell 162:184-97
Shroff, Emelyn H; Eberlin, Livia S; Dang, Vanessa M et al. (2015) MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A 112:6539-44
Spitzer, Matthew H; Gherardini, Pier Federico; Fragiadakis, Gabriela K et al. (2015) IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. Science 349:1259425
Sagiv-Barfi, Idit; Kohrt, Holbrook E K; Czerwinski, Debra K et al. (2015) Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 112:E966-72
Casey, Stephanie C; Vaccari, Monica; Al-Mulla, Fahd et al. (2015) The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis 36 Suppl 1:S160-83
O'Gorman, William E; Hsieh, Elena W Y; Savig, Erica S et al. (2015) Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus. J Allergy Clin Immunol 136:1326-36

Showing the most recent 10 out of 523 publications